Amarin Corporation plc (AMRN)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor, so I begin with the business, not the stock chart. Amarin sells VASCEPA, a single prescription omega-3 product. That is a narrow foundation, and the filed numbers show why a moat matters: revenue fell from $306.9 million in fiscal year 2023 to $228.6 million in fiscal year 2024 to $213.6 million in fiscal year 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $42.2 million, down from $72.7 million in fiscal Q2 2025, the quarter ended 2025-06-30. The net loss narrowed to $7.7 million from $14.1 million, which is progress, but the company still lost $38.8 million in fiscal year 2025 after losing $82.2 million in fiscal year 2024 and $59.1 million in fiscal year 2023. Financial health is mixed. Debt is low, D/E 0.02 per FairStock, and trailing free cash flow was $15.6 million, a 5.1% FCF yield. Yet Altman Z-score is -2.00, suggesting distress, and Piotroski F-score is 5/9. At the 2026-10-13 close of $11.58, market cap is $307.8 million. P/B is 0.55 and P/E is -9.65 per FairStock, so the price is below book but there are no earnings to capitalize. FairStock's score is 56/100, and the Lynch category is none because of losses in each of the last four years. Graham would ask whether assets provide a true margin of safety; Buffett would ask whether the product has durable pricing power. The data so far show falling sales, not durable economics. I would need evidence of revenue stabilization and sustainable profit before calling this a sound value.

In plain English: Amarin sells VASCEPA, a prescription omega-3 medicine for high triglycerides. The business looks weak right now: it is losing money, and sales have fallen sharply from a year earlier. The stock trades below the value of its net assets, but until the company stops losing money and sales stop falling, it is hard to call the price truly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer